Trogenix Emerges from Stealth with Precision Gene Therapy Platform to Target Aggressive Cancers

Trogenix Ltd has launched its Odysseus platform, leveraging Synthetic Super-Enhancer (SSE) technology to advance precision viral immunotherapy for aggressive cancers.

Continue ›››

Novartis Expands Radiopharmaceutical Portfolio with $745M Deal with Ratio Therapeutics

Novartis has struck a licensing agreement with Boston-based biotech Ratio Therapeutics, securing global rights to a promising cancer candidate targeting …

Continue ›››

Medable Adds Generative AI to Simplify and Speed Up Clinical Trials

Medable Inc. has introduced generative AI capabilities to its Medable Studio platform to streamline and accelerate digital and decentralized clinical …

Continue ›››

40,000 NHS Healthcare Workers to Get AI Tool That Cuts Admin Time by 80%

A new partnership between Corti and BigHand will bring a specialized AI tool to 40,000 healthcare workers across 76 NHS …

Continue ›››

Survey Highlights Critical Need for AI Adoption in Regulatory Affairs Amid Unsustainable Workloads

New research commissioned by ArisGlobal, a provider of life sciences technology solutions, reveals that surging regulatory workloads are forcing life …

Continue ›››

What will be the key trends in AI innovation in the Pharmaceutical Industry in 2025?

The pharmaceutical industry is undergoing transformation thanks to artificial intelligence (AI) in particular GenAI. From drug discovery and manufacturing to …

Continue ›››

Immunai and Teva Collaborate to Advance Clinical Trials in Oncology and Immunology

Immunai, an AI-driven biotech company focused on mapping the human immune system, has partnered with Teva Pharmaceuticals in a multi-year …

Continue ›››

Enveda Advances AI-Discovered, Nature-Derived Drug ENV-294 to Phase 1 Trials

Enveda, a biotechnology company transforming nature’s chemistry into medicines using AI, has announced the FDA clearance of an investigational new …

Continue ›››

Genesis Therapeutics Collaborates with NVIDIA and Secures Additional NVentures Funding to Accelerate AI-Driven Drug Discovery

Genesis Therapeutics has announced a collaboration with NVIDIA to advance its AI platform, GEMS (Genesis Exploration of Molecular Space). The …

Continue ›››

Recursion Unveils OpenPhenom-S/16: A Foundation Model for Microscopy Data

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) has released OpenPhenom-S/16, a new publicly accessible foundation model, on Google Cloud’s Vertex AI Model …

Continue ›››

Schrödinger and Novartis Forge Partnership to Scale Computational Drug Discovery

Schrödinger, Inc. (Nasdaq: SDGR) has entered a collaboration and licensing agreement with Novartis to advance drug discovery efforts on multiple …

Continue ›››

Recursion Unveils New Foundation Model for Molecular Property Prediction

Recursion researchers have introduced MolE, a new model aimed at improving predictions of chemical and biological properties of molecules by …

Continue ›››